CAS: 83-07-8; 4-Aminoantipyrine

相似化合物

22198-72-7 519-98-2 129476-61-5

上下游产品

CAS号885-11-0 亚硝基安替比林 | CAS号60-80-0 安替比林 | CAS号58-15-1 氨基比林 | CAS号135182-38-6 4-[(2,2,2-Trich... | CAS号5702-68-1 N-(1,5-dimethyl... | CAS号68-89-3 安乃近 | CAS号7647-01-0 盐酸 | CAS号7664-93-9 硫酸 | CAS号1759-26-8 4-Sulfate Amino... | CAS号3608-86-4 2-氯-n-(1,5-二甲基-... | CAS号3615-24-5 异丙氨基比林 | CAS号2139-47-1 尼芬那宗 | CAS号617-94-7 2-苯基-2-丙醇 | CAS号26084-35-5 1,3-双-(1,5-二甲基-... | CAS号26690-91-5 N-(1,5-dimethyl... | CAS号83-15-8 4-乙酰氨基安替比林 | CAS号881-05-0 5-methyl-2-phen... | CAS号38604-70-5 N-methyl-N-phen... | CAS号5142-72-3 4-amino-2,4-dih...

4-(甲氨基)安替比林置于soybean Lipoxygenase,双氧水,Horseradish Peroxidase体系中,用 Aq. Phosphate Buffer 作为反应溶剂,化学反应 0.08H,反应生成 4-氨基安替比林
参考文献:N-甲基-4-氨基安替比林的n-脱甲基作用,间苯二酚的主要代谢物.
标题:N-甲基-4-氨基安替比林的n-脱甲基作用,间苯二酚的主要代谢物.
摘要:灭蚁灵是一种在某些国家经常使用的古老镇痛药.苯甲咪唑的活性代谢产物是非酶促反应生成的n-甲基-4-氨基安替比林(4-Maa)及其去甲基化产物4-氨基安替比林(4-Aa).先前的研究表明,可以通过肝细胞色素p450(cyp)3A4进行4-Maa去甲基化,但其他cyp的可能贡献尚不清楚.使用人肝微粒体(hlm),肝匀浆和heparg细胞,我们可以通过cyp确认4-Maa去甲基化.基于cyp诱导(heparg细胞)和cyp抑制(hlm),我们可以确定cyp2B6,2C8,2C9和3A4是4-Maa去甲基化的主要贡献者.hlm的4-Maa脱甲基速率为280 Pmol / Mg蛋白质/小时,太低,无法说明人体内的4-Maa脱甲基.由于过氧化物酶可以进行n-去甲基化,我们调查了辣根过氧化物酶和人类髓过氧化物酶(mpo).辣根过氧化物酶可以有效地使4-Maa脱甲基,具体取决于过氧化氢的浓度.对于mpo来说也是如此.该反应可饱和,Km为22
DOI:10.1016/j.Ejps.2018.05.003

专利信息

专利号:US-2012177593-A1
优先权日:2009-07-20
标 题 :Synthesis of dendrimer conjugates
发明人：BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

专利号:US-10768157-B2
优先权日:2015-10-20
标 题:Materials and methods for the detection of trace amounts of substances in biological and environmental samples
发明人：KABIR ABUZAR; FURTON KENNETH G
权利人:KABIR ABUZAR; FURTON KENNETH G; THE FLORIDA INTERNATIONAL UNIV BOARD OF TRUSTEES
摘要:The subject invention provides chemical compositions and synthesis strategies to create molecularly imprinted polymers (MIPs) via sol-gel processes. In a specific embodiment, the subject invention utilizes a(n) organic, inorganic, or metallic template analyte to create a hybrid organic-inorganic or inorganic three-dimensional network possessing cavities complementary to the shape, size, and functional orientation of the template molecule or ions. The subject invention further pertains to the use of the novel MIPs as selective solid phase extraction (SPE) sorbents for pre-concentration and clean-up of trace substances in biological and environmental samples. Synthesis of other molecularly imprinted polymers with environmental, pharmaceutical, chemical, clinical, toxicological, and national security implications can be conducted in accordance with the teachings of the subject invention.

专利号:US-9145368-B2
优先权日:2011-12-15
标 题 :Organocatalytic synthesis of chiral pyrazolidines and their analogues
发明人：KUMAR BOOPATHI SENTHIL; VENKATARAMASUBRAMANIAN VAITHIYANATHAN; SUDALAI ARUMUGAM
权利人:COUNCIL SCIENT IND RES
摘要:Disclosed herein is a highly enantio- (75 to 98% ee) and diastereoselective (99 to 100% de) synthesis of functionalized pyrazolidines via tandem a-amination-Corey Chaykovsky reaction of alpha unsubstituted aldehydes.

专利号:US-9579636-B1
优先权日:2014-02-26
标 题:Method for synthesis of functional ceramic materials
发明人：Roy Aaron Joseph; WARD TIMOTHY L; SEROV ALEXEY; ATANASSOV PLAMEN B
权利人:Roy Aaron Joseph; WARD TIMOTHY L; SEROV ALEXEY; ATANASSOV PLAMEN B; STC UNM
摘要:Novel materials having high surface area rendering them suitable for a variety of applications including, but not limited to: catalysts for methane reforming; ammonia synthesis; alcohol synthesis from syngas; hydrodesulfurization; electrocatalysis for hydrogen evolution reaction; and as corrosion-resistant supports for platinum in PEM fuel cells. In general the method comprises the formation of a high-surface area refractory metal-based material using a novel synthesis pathway that avoids the production of intermediate oxide. The method may include the in situ formation of a sacrificial support that can be removed using non-aggressive means, such as, for example, chemical etching with a mild acid or by altering reaction conditions.

专利号:US-8304409-B2
优先权日:2002-07-03
标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
发明人：EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA
摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

专利号:US-2023416934-A1
优先权日:2022-06-27
标 题 :Acid-free pyrolytic synthesis of m-n-c catalyst
发明人：DELAFONTAINE LAURENT; ATANASSOV PLAMEN
权利人:UNIV CALIFORNIA
摘要:A method for making a catalyst includes a step of forming a first reaction mixture that includes a metal source, a nitrogen source, and at least one silica template. Characteristically, the at least one silica template including silica particles. A combination of the first reaction mixture and a fluorinated polymer is mechanochemically mixed to form a first pre-pyrolysis powder. A first pyrolysis of the first pre-pyrolysis powder is performed at a first temperature greater than about 800° C. under an inert atmosphere to form a first pyrolyzed composition. Advantageously, at least a portion of silica particles is removed and mesostructured carbon is formed. The first pyrolyzed composition is optionally mechanochemically mixing to form a second pre-pyrolysis powder. A second pyrolysis of the first first pyrolyzed composition or the second pre-pyrolysis powder is performed under a reductive atmosphere at a second temperature that is greater than about 800° C. to form a final catalyst powder.